Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway. Show More...
-
Website https://www.bergenbio.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.83 NOK
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share NOK -239.35 -2.6 -3.99 -3.59 -3.43 -3.35 Dividends NOK Payout Ratio % * Shares Mil 50.0 50.0 46.0 54.0 58.0 61.0 Book Value Per Share * NOK 7.91 7.06 4.51 4.37 Free Cash Flow Per Share * NOK -3.27 -3.44 -3.36 Return on Assets % -87.52 -101.04 -65.21 -50.25 -61.39 -52.87 Financial Leverage (Average) 1.27 1.14 1.09 1.12 1.23 1.14 Return on Equity % -111.37 -119.07 -72.36 -55.77 -71.55 -60.36 Return on Invested Capital % -111.34 -119.85 -73.46 -56.78 -72.17 -62.8 Interest Coverage -278.48 -294.83 Current Ratio 6.8 8.19 11.29 9.1 5.32 7.93 Quick Ratio 6.09 7.59 10.9 8.66 5.0 7.69 Debt/Equity 0.02